Gufic Biosciences Limited

Valuation mismatch: PE of 65.95 against ROE of 10.14% implies steep pricing relative to current capital returns; verify if near-term earnings growth or multiple expansion is embedded in market expectations

Profit inconsistency: Net profit ranges ₹12–22 Cr and EPS ₹1.2–2.18 across recent quarters; verify drivers of quarterly volatility and underlying earnings quality

Margin volatility: OPM swings from 14.25% (Jun 2025) to 18.75% (Mar 2026), a 450 bps range; verify if recent recovery reflects durable cost control or one-time favorability

Thin institutional participation: FII 0.46% and DII 3.68% suggest limited buy-side research coverage; verify analyst follow-up and market-depth for sizeable trades

Operating margin expansion: OPM improved from 14.88% (Jun 2025) to 18.75% (Mar 2026), a 387 bps gain — verify if cost structure optimization or product mix shift, and whether repeatable

Stable revenue base: Quarterly revenue maintained at ₹223–252 Cr across eight recent quarters — verify if current scale can support reacceleration through market demand or portfolio depth

Cash generation capacity: Latest quarter net profit of ₹21.9 Cr and EPS of ₹2.18 (Mar 2026) with regular dividend payouts — verify reinvestment intensity and capital allocation toward growth vs. returns